AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Deubiquitinase DESI2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9BSY9

UPID:

DESI2_HUMAN

Alternative names:

Desumoylating isopeptidase 2; PPPDE peptidase domain-containing protein 1; Protein FAM152A

Alternative UPACC:

Q9BSY9; B1APK6; Q5VVC6; Q9NYS2; Q9Y3E4

Background:

Deubiquitinase DESI2, also known as Desumoylating isopeptidase 2, PPPDE peptidase domain-containing protein 1, and Protein FAM152A, exhibits deubiquitinating activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. It specifically deubiquitinates 'Lys-48'-linked polyubiquitination of RPS7, leading to its stabilization, a process crucial for protein homeostasis and cellular functions.

Therapeutic significance:

Understanding the role of Deubiquitinase DESI2 could open doors to potential therapeutic strategies. Its unique ability to regulate protein stability through deubiquitination positions it as a key player in cellular homeostasis and disease mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.